$FRO

Crude oil settled near $100/barrel as Iran and Gulf states plan talks on Strait of Hormuz. IEA, EIA, and OPEC differ on demand forecasts. Valero (VLO) and Marathon (MPC) reported strong Q2 earnings, with high refining margins. Frontline (FRO) saw increased tanker earnings due to rerouted crude flows. Key events this week include Hormuz talks and Fed rate decision.

Crude oil prices hovered near $100 per barrel as Gulf states prepared to meet with Iran to discuss shipping through the Strait of Hormuz. The IEA expects global oil demand to fall by 2.5 million barrels per day in 2026, while the EIA raised its 2026 Brent price forecast to $90. Refining margins and tanker earnings surged, benefiting companies like Valero, Marathon Petroleum, and Frontline. Global oil inventories have dropped by 507 million barrels since the war began, with August seeing a 95 mil

Frontline plc (FRO) declared a special one-time dividend of $0.80 per share after selling two VLCCs. This adds to the previously announced $2.61 dividend for Q2 2026. The ex-dividend dates are September 17 (Oslo) and 18 (NYSE), with payment on September 28, 2026, according to the company.

Frontline plc (FRO) rose 3.8% after reporting record quarterly profit, declaring a $2.61 dividend, and announcing a special $0.80 dividend from vessel sales. The company also secured new charters at high rates, amid surging VLCC freight rates. Institutional investors have recently increased their positions in FRO.

Bayer's Hyrnuo (sevabertinib) received FDA approval for first-line treatment of advanced HER2-mutant NSCLC, based on trial data showing 75% response rate. The drug now competes with Boehringer Ingelheim's Hernexeos (zongertinib), also approved for this use. Analysts predict modest sales for both, with Hernexeos expected to reach $54M and Hyrnuo $49M by 2032 in major markets. Both companies are conducting confirmatory trials for full approval.

AstraZeneca's Imfinzi and Amgen's Imdelltra combination showed significant improvement in overall survival for frontline extensive-stage small cell lung cancer (ES-SCLC) in a Phase III trial, meeting primary and secondary endpoints. The companies plan to share data with regulators, which could expand Imdelltra's market potential. Analysts forecast peak sales of over $10bn for Imfinzi and $3bn for Imdelltra by 2026-2032.

Frontline, a tanker operator, signed $235 million in time-charter contracts for four VLCCs. Two new VLCCs have one-year contracts at $120,000/day, and two older VLCCs have one and three-year contracts at $90,000 and $75,000/day, respectively. Frontline reported a Q2 2026 operating profit of $659.2 million and sold two VLCCs for $270 million. The company operates 75 vessels, including 38 VLCCs.

Frontline Financial Services reported a FY2025-26 profit of Rs 0.0008 crore on Rs 2.94 crore income. Auditor M/s. J.S Shah and Co. issued a disclaimer, citing missing asset documentation and internal control weaknesses. The company's AGM is set for September 30, 2026, with no dividend declared. Auditor raised concerns over asset verification and valuation.

Frontline plc reported Q2 2026 revenue of $1.02 billion and net income of $659.17 million, declaring a $2.61 per share dividend. The company's strong results highlight current market conditions, but analysts warn of potential risks from freight rate normalization and long-term energy transitions.

Frontline (FRO) reported its best quarterly profit ever in Q2 2026, with net income of $659.2M and revenue of $943.3M. The company declared a $2.61 per share dividend. Earnings were driven by strong spot-market rates across vessel classes, supported by geopolitical disruptions. Management noted lower borrowing costs and emphasized near-term cash generation. The outlook depends on sustained high freight rates and market conditions. (349 characters)